GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » 9-Day RSI

IRLAB Therapeutics AB (OSTO:IRLAB A) 9-Day RSI : 60.93 (As of May. 28, 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-28), IRLAB Therapeutics AB's 9-Day RSI is 60.93.

The industry rank for IRLAB Therapeutics AB's 9-Day RSI or its related term are showing as below:

OSTO:IRLAB A's 9-Day RSI is ranked worse than
87.12% of 1568 companies
in the Biotechnology industry
Industry Median: 43.775 vs OSTO:IRLAB A: 60.93

Competitive Comparison of IRLAB Therapeutics AB's 9-Day RSI

For the Biotechnology subindustry, IRLAB Therapeutics AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's 9-Day RSI falls into.



IRLAB Therapeutics AB  (OSTO:IRLAB A) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRLAB Therapeutics AB  (OSTO:IRLAB A) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


IRLAB Therapeutics AB 9-Day RSI Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines